Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), a biopharmaceutical company focused on innovative assets and biotech solutions, has announced its participation in the ArcStone-Kingswood Growth Summit on September 26, 2024, in Toronto, ON. Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the event, which features over 30 public and private companies and 47 sponsors from around the world.
The presentation is scheduled for 2:45 p.m. to 2:55 p.m., followed by a 2-minute Q&A session. Mr. Sawyer will discuss the company's growth potential and connect with key investors. The summit aims to create meaningful public companies that drive value for both management and investors. It will be held at the Sheraton Hotel in downtown Toronto.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), una compagnia biofarmaceutica focalizzata su asset innovativi e soluzioni biotecnologiche, ha annunciato la sua partecipazione al Summit sulla Crescita ArcStone-Kingswood il 26 settembre 2024, a Toronto, ON. Jason Sawyer, Responsabile Finanza e Fusioni e Acquisizioni, presenterà all'evento, che conta oltre 30 aziende pubbliche e private e 47 sponsor provenienti da tutto il mondo.
La presentazione è prevista per le 14:45 alle 14:55, seguita da una sessione di domande e risposte di 2 minuti. Il Sig. Sawyer discuterà il potenziale di crescita dell'azienda e si connetterà con investitori chiave. L'obiettivo del summit è creare aziende pubbliche significative che generino valore sia per la direzione che per gli investitori. Si terrà presso il Sheraton Hotel nel centro di Toronto.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), una empresa biofarmacéutica centrada en activos innovadores y soluciones biotecnológicas, ha anunciado su participación en el Summit de Crecimiento ArcStone-Kingswood el 26 de septiembre de 2024, en Toronto, ON. Jason Sawyer, Jefe de Finanzas y Fusiones y Adquisiciones, realizará una presentación en el evento, que contará con más de 30 empresas públicas y privadas y 47 patrocinadores de todo el mundo.
La presentación está programada para 2:45 p.m. a 2:55 p.m., seguida de una sesión de preguntas y respuestas de 2 minutos. El Sr. Sawyer hablará sobre el potencial de crecimiento de la empresa y se conectará con inversores clave. El objetivo del summit es crear empresas públicas significativas que generen valor tanto para la dirección como para los inversores. Se llevará a cabo en el Hotel Sheraton en el centro de Toronto.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91)은 혁신 자산과 생명공학 솔루션에 초점을 맞춘 생명공학 제약 회사로, 2024년 9월 26일 온타리오주 토론토에서 개최되는 ArcStone-Kingswood 성장 정상 회담에 참여한다고 발표했습니다. 제이슨 소여 금융 및 인수합병 책임자가 발표를 진행할 예정이며, 이번 행사에는 30개 이상의 공공 및 민간 기업과 전 세계 47개 스폰서가 자리합니다.
발표는 오후 2시 45분부터 오후 2시 55분까지 예정되어 있으며, 이후 2분간의 Q&A 세션이 이어집니다. 소여 씨는 회사의 성장 잠재력에 대해 논의하고 주요 투자자들과 연결할 것입니다. 이번 정상 회담의 목표는 경영진과 투자자 모두에게 가치를 창출하는 의미 있는 공개 기업을 만드는 것입니다. 행사는 토론토 시내의 쉐라톤 호텔에서 개최됩니다.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), une entreprise biopharmaceutique axée sur des actifs innovants et des solutions biotechnologiques, a annoncé sa participation au Sommet de Croissance ArcStone-Kingswood le 26 septembre 2024 à Toronto, ON. Jason Sawyer, Responsable des Finances et des Fusions-Acquisitions, fera une présentation lors de l'événement, qui réunira plus de 30 entreprises publiques et privées ainsi que 47 sponsors du monde entier.
La présentation est prévue de 14h45 à 14h55, suivie d'une session de questions-réponses de 2 minutes. M. Sawyer discutera du potentiel de croissance de l'entreprise et établira des connexions avec des investisseurs clés. L'objectif du sommet est de créer des entreprises publiques significatives qui génèrent de la valeur tant pour la direction que pour les investisseurs. Il se tiendra à l'Hôtel Sheraton dans le centre-ville de Toronto.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), ein biopharmazeutisches Unternehmen, das sich auf innovative Vermögenswerte und biotechnologische Lösungen konzentriert, hat seine Teilnahme am ArcStone-Kingswood Wachstumsgipfel am 26. September 2024 in Toronto, ON angekündigt. Jason Sawyer, Leiter Finanz- und M&A, wird auf der Veranstaltung präsentieren, an der über 30 öffentliche und private Unternehmen sowie 47 Sponsoren aus der ganzen Welt teilnehmen.
Die Präsentation ist für 14:45 bis 14:55 Uhr angesetzt, gefolgt von einer 2-minütigen Q&A-Session. Herr Sawyer wird das Wachstumspotenzial des Unternehmens diskutieren und Kontakt zu wichtigen Investoren aufnehmen. Der Gipfel hat das Ziel, bedeutende öffentliche Unternehmen zu schaffen, die sowohl für das Management als auch für die Investoren Werte erzeugen. Er findet im Sheraton Hotel im Zentrum von Toronto statt.
- None.
- None.
TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM) (CSE:QNTM) (FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the ArcStone-Kingswood Growth Summit held on September 26, 2024, in Toronto, ON. The event will feature over 30 public and private companies and 47 sponsors from around the world.
Mr. Jason Sawyer, Head of Finance and Mergers and Acquisitions, will be a speaker and participate in panels discussing the growth potential of the company and connecting with key investors. This event is intended to create meaningful public companies that drive value for both management and investors. The event is being held at the Sheraton Hotel in downtown Toronto, ON.
Presentation time slot: 2:45p.m. - 2:55p.m. followed by 2 minutes of Q&A.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun it out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of
About ArcStone Securities and Investments Corp.
ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in New York and Toronto. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.
**For more information or to register for the conference, please contact**:
Investor Relations
ArcStone Securities and Investments Corp.
Email: info@arcstonesecurities.com
Jack Bensimon, B.A. (Hon), LL.M., CAMS
Managing Partner
ArcStone Securities and Investments Corp.
T: (416) 985-0757
E: jack@arcstoneglobalsecurities.com
Cautionary Note Regarding Forward-Looking Information
This press release contains certain "forward-looking statements" within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "anticipates", "expects", "is expected", "scheduled", "estimates", "pending", "intends", "plans", "forecasts", "targets", or "hopes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "will", "should" "might", "will be taken", or "occur" and similar expressions) are not statements of historical fact and may be forward-looking statements. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company conducting future phase 2 studies; the Company's focus on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company's intention to utilize its large tax loss to offset future tax payable obligations against future profits; the Company's intention to retain
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company conducting future phase 2 studies; the Company's assessment of market conditions, its ability to gain market share, and its potential competitive edge are accurate; the Company will have the ability to carry out its plans with respect to its new innovation and offerings, including its ability to conduct research and development of Lucid-MS; the Company will retain
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to carry out its plans with respect to its new innovation, offerings and studies; the Company's inability to utilize its tax loss; the Company's inability to retain
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884
Investor Relations:
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
Contact Information:
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884
SOURCE: Quantum Biopharma Ltd.
View the original press release on accesswire.com
FAQ
When and where is Quantum BioPharma (QNTM) presenting at the ArcStone-Kingswood Growth Summit?
Who will be representing Quantum BioPharma (QNTM) at the ArcStone-Kingswood Growth Summit?
What is the presentation time for Quantum BioPharma (QNTM) at the ArcStone-Kingswood Growth Summit?
How many companies and sponsors will be featured at the ArcStone-Kingswood Growth Summit where Quantum BioPharma (QNTM) is presenting?
